Serum Carnitine Level and Its Associated Factors in Patients With Chronic Viral Hepatitis

Azin Nassiri; Simin Dashti-Khavidaki; Hossein Khalili*; Mohsen Nassiri-Toosi; Alireza Abdollahi


Future Virology. 2014;9(4):373-383. 

In This Article

Future Perspective

More studies are needed to compare carntine serum level in patients with chronic HBV and HCV infection. Furthermore, predisposing factors for carnitine deficiency in patients with chronic HBV infection may differ from patients with chronic HCV infection. Evaluation of serum carnitine level along with tissue carnitine content may provide a better indicator for evaluation of the human body carnitine pool and role of carnitine in the pathogenesis of viral hepatitis. Carnitine status in patients with acute viral hepatitis is another issue than has potential for further evaluation. Cause of elevation in serum carnitine level in patients with cirrhosis in comparison with noncirrhotic individuals needs to be clarified in future research. Although several studies demonstrated the beneficial effects of carnitine supplementation on improving the clinical manifestations of chronic hepatitis, adverse effects of standard treatments and higher rate of sustained virological response, there is not any consensus statement regarding carnitine dose and duration in patients with chronic viral hepatitis.